The proportion of cardiac catheterization patients with SGLT2 inhibitor prescriptions before the procedure showed modest but steady growth, increasing from 0.5% in 2018 to 1.6% in 2023 (Figure 4)
You may be ready to stop or down-titrate if: Cycles are regular (2635 days) Ovulation is consistent Luteal phase is stable (1014 days) Weight loss is ~510% Metabolic markers have improved At this point, the primary fertility benefit of GLP-1s has likely been achieved
Diabetes is associated with an increased risk of developing dementia and neurodegenerative diseases, which is inversely related to the degree of glucose tolerance and directly to the disease duration [16]
D.tefnescuV
Projections of the size of the weight control markets have varied from $40B to $150B annually
That said, collaboration is wise: communicate with the patients PCP, dont usurp necessary medical workups (rule out endocrine causes, get baseline labs), and refer to specialists (endocrinology, cardiology) when appropriate